Spago Nanomedical AB (publ) (STO:SPAGO)

Market Cap	83.03M +37.4%
Revenue (ttm)	3.81M -38.1%
Net Income	-26.28M
EPS	-0.05
Shares Out	798.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,296
Open	0.1040
Previous Close	0.1020
Day's Range	0.1040 - 0.1125
52-Week Range	0.0800 - 0.3700
Beta	1.30
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a nanomedicine company, engages in the development projects based on a platform of polymeric materials for diagnosis and treatment of life-threatening and debilitating diseases in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment of liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of cancer. The company was formerly ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 6
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPAGO

Financial Performance

In 2025, Spago Nanomedical AB's revenue was 4.47 million, a decrease of -32.85% compared to the previous year's 6.66 million. Losses were -26.55 million, -18.32% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 14, 2026

Data Sources Report a data error